- Best Practices New Normal
- Digital Dentistry
- Data Security
- Implants
- Catapult Education
- COVID-19
- Digital Imaging
- Laser Dentistry
- Restorative Dentistry
- Cosmetic Dentistry
- Periodontics
- Oral Care
- Evaluating Dental Materials
- Cement and Adhesives
- Equipment & Supplies
- Ergonomics
- Products
- Dentures
- Infection Control
- Orthodontics
- Technology
- Techniques
- Materials
- Emerging Research
- Pediatric Dentistry
- Endodontics
- Oral-Systemic Health
Lab studies find ClōSYS rinse is effective against SARS-CoV-2
An in vitro laboratory analysis showed that ClōSYS Ultra Sensitive Oral Rinse reduced SARS-CoV-2 by up to 98.4% within 30 seconds.
Rowpar Pharmaceuticals, Inc., the makers of the ClōSYS brand of toothpastes, mouthwashes, and oral sprays, has announced that an in vitro laboratory analysis showed that ClōSYS Ultra Sensitive Oral Rinse reduced SARS-CoV-2 by up to 98.4% within 30 seconds without the use of any harsh chemicals such as alcohol, hydrogen peroxide, or povidone-iodine, Rowpar said in a statement.
“These are exciting and potentially groundbreaking findings,” said CEO of Rowpar Pharmaceuticals Jim Ratcliff. “We know that the COVID-19 virus can be transmitted from person to person through spray droplets from the mouth, so this is an important first step in determining whether our oral care products can make a significant impact in reducing the chances of becoming ill or infecting others. There is a lot more to learn as we follow the science, but it’s a very positive start for our rinse formula.”
The study was conducted at MRI Global, an independent laboratory in Kansas City, Missouri. MRI Global is accredited to test highly infectious viruses such as SARS-CoV-2, the virus that causes COVID-19. A second independent accredited lab, Microbac Laboratories, Inc. in Sterling, Virginia provided similar results.
These initial trials did not include testing the oral cavity but based on these results Rowpar has launched additional studies to determine whether ClōSYS over-the-counter products can help lower the transmission of the coronavirus from person-to-person.
While there is no evidence that inactivating the COVID-19 virus in the mouth will impact disease transmission, the studies reinforce the antimicrobial strength of ClōSYS products, the statement read. Clinical trials in progress at the University of California San Francisco are evaluating whether oral rinses can reduce the viral load in the mouth, which may in turn reduce the transmission of the disease.
All ClōSYS products contain a proprietary formula with Clorastan®, the trade name for stabilized chlorine dioxide, which is a safe and effective oxidant long recognized for its antimicrobial, disinfecting, and sanitizing properties. The ClōSYS formula is naturally activated by acids in saliva. Once released, Clorastan is said to disrupt and penetrate dental biofilm, killing te microbial pathogens living within and inhibiting their re-growth.
For more information, visit closys.com.
Study Shows Dental Opioid Prescribing Went Up During COVID-19 Pandemic
November 6th 2023A new study demonstrates that dental opioid prescribing increased during the peak of the COVID-19 pandemic, reinforcing the importance of non-opioid pain management solutions even during global health emergencies.
